Shuttle Pharmaceuticals shares are trading higher after it was granted U.S. patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation.
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals' shares are trading higher after being granted U.S. patent #11654157 for methods and compositions for cancer therapies, including delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation.
May 23, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharmaceuticals shares are trading higher after being granted a U.S. patent for cancer therapy methods and compositions.
The granting of the U.S. patent for cancer therapy methods and compositions is a significant milestone for Shuttle Pharmaceuticals. This development is likely to boost investor confidence in the company's potential for growth and innovation, leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100